Literature DB >> 9841817

Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania.

A Obasi1, F Mosha, M Quigley, Z Sekirassa, T Gibbs, K Munguti, J Todd, H Grosskurth, P Mayaud, J Changalucha, D Brown, D Mabey, R Hayes.   

Abstract

A serosurvey was conducted in a random sample of 259 women and 231 men in 12 rural communities in Mwanza Region, Tanzania, using a type-specific ELISA for Herpes simplex virus type 2 (HSV-2) infection. Seroprevalence rose steeply with age to approximately 75% in women >=25 years old and 60% in men >=30. After adjusting for age and residence, HSV-2 prevalence was higher in women who were married, in a polygamous marriage, Treponema pallidum hemagglutination assay (TPHA)-positive, had more lifetime sex partners, or who had not traveled. Prevalence was higher in men who were married, had lived elsewhere, had more lifetime partners, had used condoms, or were TPHA-positive. HSV-2 infection was significantly associated with recent history of genital ulcer. The association between HSV-2 infection and lifetime sex partners was strongest in those <25 years old in both sexes. This association supports the use of HSV-2 serology as a marker of risk behavior in this population, particularly among young people.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9841817     DOI: 10.1086/314555

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  53 in total

Review 1.  Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmes.

Authors:  N O'Farrell
Journal:  Sex Transm Infect       Date:  1999-12       Impact factor: 3.519

2.  Hormonal markers of susceptibility to sexually transmitted infections: are we taking them seriously?

Authors:  L Brabin
Journal:  BMJ       Date:  2001-08-18

Review 3.  Recent advances: Sexually transmitted infections.

Authors:  R J Gilson; A Mindel
Journal:  BMJ       Date:  2001-05-12

Review 4.  Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries.

Authors:  S Mullick; D Watson-Jones; M Beksinska; D Mabey
Journal:  Sex Transm Infect       Date:  2005-08       Impact factor: 3.519

Review 5.  HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa.

Authors:  Laith J Abu-Raddad; Joshua T Schiffer; Rhoda Ashley; Ghina Mumtaz; Ramzi A Alsallaq; Francisca Ayodeji Akala; Iris Semini; Gabriele Riedner; David Wilson
Journal:  Epidemics       Date:  2010-09-15       Impact factor: 4.396

Review 6.  It takes 2: partner attributes associated with sexually transmitted infections among adolescents.

Authors:  Andrea Swartzendruber; Jonathan M Zenilman; Linda M Niccolai; Trace S Kershaw; Jennifer L Brown; Ralph J Diclemente; Jessica M Sales
Journal:  Sex Transm Dis       Date:  2013-05       Impact factor: 2.830

7.  Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations.

Authors:  Eddy van Dyck; Anne Buvé; Helen A Weiss; Judith R Glynn; David W G Brown; Bénédicte De Deken; John Parry; Richard J Hayes
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

8.  Virus-encoded b7-2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice.

Authors:  Sri P Vagvala; Lydia G Thebeau; Saydra R Wilson; Lynda A Morrison
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

9.  Sexually transmitted infections and male circumcision: a systematic review and meta-analysis.

Authors:  Robert S Van Howe
Journal:  ISRN Urol       Date:  2013-04-16

10.  Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa.

Authors:  R G White; E E Freeman; K K Orroth; R Bakker; H A Weiss; N O'Farrell; A Buvé; R J Hayes; J R Glynn
Journal:  Sex Transm Infect       Date:  2008-10       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.